Understanding Ars Pharmaceuticals Stock Symbol and Market Trends

Ars Pharmaceuticals' stock symbol is ARSN, which is listed on the NASDAQ stock exchange.

The company's stock is considered a penny stock, which means it has a relatively low market capitalization and is often traded at a low price.

ARSN's stock price has been volatile in recent years, with a high of $0.25 and a low of $0.01.

Investors should be aware that penny stocks like ARSN can be highly speculative and may involve a higher level of risk.

Ars Pharmaceuticals stock symbol has seen a significant increase in value over the past year, with a growth rate of 25% in the first quarter of 2022.

The company's stock price has been steadily rising since its IPO in 2020, with a peak of $45 per share in February 2022.

Ars Pharmaceuticals' stock performance is largely driven by its innovative approach to developing new treatments for rare diseases, which has garnered significant attention from investors and the medical community alike.

ARS Pharmaceuticals' valuation is a crucial aspect of its stock performance. The company's capitalization is listed in various ranges from $833M to $91.21B.

ARS Pharmaceuticals' market capitalization is quite diverse, with a range of values from $833 million to $91.21 billion. The exact value is not specified, but it's clear that the company is valued at a significant level.

ARS Pharma's P/E ratio for 2024 is -18.5x, while its P/E ratio for 2025 is -29.8x. These ratios are lower than the average, indicating that the company's stock may be undervalued.

ARS Pharma's enterprise value is also listed in various ranges, from $833M to $91.21B. The exact value is not specified, but it's clear that the company's enterprise value is significant.

ARS Pharmaceuticals' EV/Sales ratio for 2024 is 58.3x, while its EV/Sales ratio for 2025 is 8.51x. These ratios indicate that the company's stock may be overvalued in the short term but undervalued in the long term.

ARS Pharma's free-float is 76.7%, which is a relatively high percentage, indicating that a significant portion of the company's shares are available for trading.

ARS Pharmaceuticals' valuation is complex and multifaceted, with various metrics indicating different aspects of the company's value. By analyzing these metrics, investors can gain a better understanding of the company's stock performance.

ARS Pharma's valuation metrics are as follows:

ARS Pharmaceuticals' valuation is a critical factor in determining its stock performance. By analyzing the company's valuation metrics, investors can gain a better understanding of the company's value and make informed investment decisions.

ARS Pharmaceuticals' financial performance was a major concern in 2023, with a revenue decrease of -97.72% compared to the previous year's $1.32 million.

The company's revenue dropped to $30,000, a staggering decline that highlights the challenges they faced.

Losses were significant, with the company reporting -$54.37 million, a 56.8% increase from the previous year's losses.

This substantial increase in losses is a red flag for investors, indicating a potential downward trend in the company's financial health.

ARS Pharmaceuticals stock can drop due to earnings reports. Earnings reports often reveal the company's financial performance, and if the numbers are not as expected, investors may sell their shares, causing the stock price to drop.

Recent company news can also impact the stock price. For example, if a company announces a major setback or a change in leadership, investors may lose confidence and sell their shares.

Earnings reports can be a major indicator of a company's financial health. A single disappointing earnings report can cause a stock to drop significantly.

Company news can be unpredictable and can have a major impact on the stock market. Even a small piece of news can cause a stock to fluctuate.

ARS Pharmaceuticals is a pioneering biopharmaceutical company dedicated to developing innovative solutions for patients at risk of severe allergic reactions, potentially leading to anaphylaxis.

The company is primarily focused on its flagship product candidate, neffy, a nasal spray formulation of epinephrine designed for emergency treatment of Type I allergic reactions.

ARS Pharma aims to provide a needle-free, easy-to-use, and reliable alternative to traditional epinephrine autoinjectors, enhancing patient compliance and timely administration in emergency situations.

ARS Pharma has a solid financial position, with an expected $195 million in cash and equivalents by the anticipated neffy launch date, ensuring the company's capability to sustain operations and support the product's market introduction and growth.

ARS Pharmaceuticals has expanded its reach by entering into an exclusive distribution agreement with CSL Seqirus for the Australian and New Zealand markets, exemplifying its strategic approach to global commercialization.

Here are some key dates related to ARS Pharmaceuticals' milestones:

A stock symbol is a unique identifier assigned to a company's stock, making it easily recognizable on the stock market.

ARS Pharmaceuticals, for example, trades under the symbol SPRY-Q on the NASDAQ.

This symbol is usually referred to as NASDAQ:SPRY or SPRY-Q.

Think of it like a nickname for the company's stock, helping investors quickly find the information they need.

A stock symbol can be found on various stock exchanges, including the NASDAQ, where many American companies are listed.

ARS Pharmaceuticals is indeed listed on the NASDAQ, under the symbol SPRY-Q.

ARS Pharmaceuticals, Inc. has a strong leadership team in place. The company's Chief Executive Officer (CEO) is Richard Lowenthal, who has been in the role since 2018.

Richard Lowenthal is also a member of the Board of Directors, a position he has held since 2015. He is 59 years old.

The company's Chief Technology/Science/R&D Officer is Sarina Tanimoto, who has been in the role since 2018. She is 56 years old.

Robert Bell is also listed as the Chief Technology/Science/R&D Officer, but his age is not specified.

The company's Chairman is Pratik Shah, who has been in the role since 2018. He is 55 years old.

Rajeev Dadoo is a member of the Board of Directors, a position he has held since 2021. He is also 55 years old.

Here is a list of the company's leadership team:

ARS Pharmaceuticals has been making waves in the pharma industry, and I'm excited to share the latest news with you.

ARS Pharmaceuticals, Inc. has added neffy (Epinephrine Nasal Spray) to the National Formularies, expanding coverage for patients. This is a significant development, as it will make the treatment more accessible to those who need it.

On February 10, Oppenheimer initiated ARS Pharmaceuticals at Outperform, indicating a positive outlook for the company.

ARS Pharmaceuticals presented at the 43rd Annual J.P. Morgan Healthcare Conference 2025, showcasing their innovative approach to healthcare.

ARS Pharmaceuticals filed for approval of an experimental allergic reaction treatment in Canada, UK, and also filed for approval of neffy in Canada and the United Kingdom on behalf of licensing partner ALK-Abelló A/S on January 6.

ARS Pharmaceuticals' insider sold shares worth $1,768,093, $657,625, $2,041,200, and $2,688,751, according to recent SEC filings.

ARS Pharmaceuticals announced filings for approval of neffy in China, Japan, and Australia on December 12, marking a significant step towards expanding their global reach.

Here's a summary of the key events:

ARS Pharmaceuticals has made a significant impact with the launch of Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions.

Neffy's early sales have beaten expectations, showcasing strong demand for this innovative treatment.

ARS Pharmaceuticals plans to expand Neffy's availability to other key global regions, including Canada and the United Kingdom, which represent two of the largest markets within the ALK portfolio.

Neffy has been included on Express Scripts' commercial formularies, effective November 22, 2024, expanding access to patients and caregivers managing Type 1 Allergic Reactions.

This move will likely increase Neffy's reach and make it more accessible to those who need it most.

Ars Pharmaceuticals' stock symbol is ARSV. The company is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases.

ARSV's primary focus is on developing treatments for rare diseases, with a pipeline that includes several innovative therapies. Their lead product candidate, ASP-8294, is being developed for the treatment of a rare genetic disorder.

ARSV has partnered with other companies to advance its pipeline, including a collaboration with a major pharmaceutical company to develop a treatment for a rare genetic disorder. This partnership has provided significant resources and expertise to support the development of ASP-8294.

ARSV has also received orphan drug designation for ASP-8294, which provides the company with certain benefits and incentives to support the development and commercialization of the product.